Welcome to our dedicated page for Esperion Therape SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Esperion Therapeutics filings document the regulatory record of a commercial-stage biopharmaceutical company focused on LDL-C lowering, cardiovascular-risk therapies, and related cardiometabolic programs. Its Form 8-K reports cover operating and financial results, clinical or regulatory disclosures, material agreements, capital-structure matters, and material-event updates tied to its commercial portfolio and development activities.
Esperion's SEC record also includes proxy disclosures on shareholder voting, board governance, executive compensation, equity awards, and pay-versus-performance information. Recent filings describe common stock registered on Nasdaq under ESPR, term-loan and credit-agreement amendments, acquisition-related financing, commercial leadership appointments, and other governance and compensation arrangements.
Wasatch Advisors reports beneficial ownership of 1,930,185 Esperion Therapeutics shares, representing 0.7% of the company’s stock class. The position carries sole voting power and sole dispositive power over all of these shares, with no shared voting or dispositive authority.
The disclosure characterizes this stake as “Ownership of 5 percent or less of a class,” indicating that Wasatch Advisors holds a relatively small fraction of Esperion’s outstanding stock.
Esperion Therapeutics, Inc. director Robert E. Hoffman reported dispositions of common stock and stock options in connection with the closing of a merger in which Esperion became a wholly owned subsidiary of Essence Parent Inc. At the July 13, 2026 effective time, his 85,153 shares of common stock were canceled and converted into the right to receive $3.16 in cash per share plus one contingent value right (CVR) per share. Outstanding restricted stock units vested in full and were similarly converted into cash based on the $3.16 per share cash consideration plus one CVR per underlying share. In-the-money stock options, including 7,040 options at a $0.87 exercise price and 40,000 options at a $1.41 exercise price, were canceled and converted into the right to receive cash equal to the excess of $3.16 over the exercise price per option share, plus one CVR per underlying share. Following these transactions, Hoffman no longer holds these securities.
Esperion Therapeutics director J. Martin Carroll reported the disposition of his equity in connection with the closing of a merger in which Essence MergerCo Inc. merged into Esperion, making Esperion a wholly owned subsidiary of Essence Parent Inc. At the effective time on July 13, 2026, 177,523 shares of common stock held by Carroll, plus 79,873 restricted stock units referenced in the footnotes, were converted into the right to receive $3.16 in cash per share and one contingent value right (CVR) per share. In addition, several in-the-money stock options covering 44,000, 32,500, and 21,000 underlying shares, with exercise prices of $0.87, $2.25, and $1.37 respectively, were canceled and converted into cash equal to the spread over $3.16 per share plus one CVR per underlying share. Following these merger-related cancellations and conversions, Carroll no longer holds these reported securities.
Esperion Therapeutics, Inc. director Jay Shepard reported issuer-directed dispositions tied to the closing of a merger with Essence Parent Inc. and Essence MergerCo Inc. on July 13, 2026. At the effective time, his 164,472 shares of common stock were canceled and converted into the right to receive $3.16 per share in cash plus one contingent value right (CVR) per share. In addition, a total of 97,500 "in-the-money" stock options with exercise prices of $0.87, $2.25 and $1.37 per share were canceled and converted into cash equal to $3.16 minus the exercise price per option share, plus one CVR for each underlying share.
Esperion Therapeutics, Inc. director Seth H. Z. Fischer reported dispositions of equity that occurred at the closing of a merger in which Essence MergerCo Inc. was merged with and into Esperion, making Esperion a wholly owned subsidiary of Essence Parent Inc. At the effective time on July 13, 2026, 141,023 shares of Esperion common stock held directly by Fischer were disposed of in a transaction with the issuer.
Each common share was converted into the right to receive $3.16 in cash per share plus one contingent value right (CVR) providing potential future cash payments upon achievement of specified milestones. All such shares ceased to be outstanding and were automatically canceled. Outstanding equity awards were also converted: 79,873 restricted stock units vested in full and were canceled for the same per-share cash amount plus one CVR per underlying share, subject to tax withholding.
In addition, three in-the-money stock option grants covering 44,000; 32,500; and 21,000 shares, with exercise prices of $0.87, $2.25, and $1.37 per share, respectively, were canceled and converted into cash equal to the excess of the $3.16 per-share cash consideration over the applicable exercise price, plus one CVR per underlying share. Following these issuer dispositions, Fischer reported no remaining direct holdings of Esperion common stock or the reported options.
Esperion Therapeutics, Inc. director John Craig Thompson reported the disposition of his equity in connection with the closing of a merger in which Essence MergerCo Inc. merged with Esperion, making Esperion a wholly owned subsidiary of Essence Parent Inc.
At the effective time on July 13, 2026, each share of Esperion common stock was converted into the right to receive $3.16 in cash per share plus one contractual contingent value right (CVR) per share, representing rights to potential future cash payments upon achievement of specified milestones. All common shares then ceased to be outstanding and were automatically canceled.
Thompson’s holdings included 79,873 restricted stock units, each converted into the cash amount equal to the per share cash consideration plus one CVR per underlying share, and 40,000 stock options with a per share exercise price of $1.00, treated as in-the-money options and canceled in exchange for cash equal to the spread over $3.16 plus one CVR per underlying share. Following these issuer dispositions, his reported direct holdings of the affected securities were reduced to zero.
Esperion Therapeutics, Inc. Chief Commercial Officer John B. Harlow Jr. reported a disposition of equity awards tied to the company’s merger with Essence Parent Inc. At the July 13, 2026 Effective Time, all common shares were converted into the right to receive $3.16 per share in cash plus one contingent value right (CVR). Harlow’s 424,536 restricted stock units vested in full and were canceled in exchange for the same cash-and-CVR merger consideration per underlying share, leaving him with no remaining directly held common shares.
Esperion Therapeutics, Inc. executive Benjamin Looker, Chief Legal Officer, reported dispositions of equity in connection with the closing of a merger in which Esperion became a wholly owned subsidiary of Essence Parent Inc. At the July 13, 2026 effective time, each share of common stock was converted into the right to receive $3.16 in cash per share plus one contingent value right (CVR), after which all common shares were canceled. Looker disposed of 667,524 shares of common stock and stock options covering 620,230 shares, which were canceled and converted into cash payments based on the excess of the $3.16 per share cash consideration over their respective exercise prices, plus CVRs, consistent with the merger terms.
Esperion Therapeutics CFO Benjamin Halladay reported the disposition of his equity in connection with Esperion’s merger with Essence Parent Inc. On July 13, 2026, all of his 705,410 shares of common stock were transferred to the issuer as part of the merger consideration, and he no longer holds these shares. In addition, stock options for 221,270 shares at $2.44, 213,000 shares at $1.50, and 200,000 shares at $2.05 per share were canceled and disposed of to the issuer. Under the merger terms, each share of common stock and each in-the-money option was converted into the right to receive $3.16 in cash per share plus one contingent value right, providing potential future cash payments if specified milestones are achieved.
Esperion Therapeutics, Inc. completed a merger in which President and CEO Sheldon L. Koenig disposed of his equity positions to the issuer at the merger effective time. The filing reports the disposition of 2,121,094 shares of common stock and several stock option grants covering 647,460, 753,000, and 642,000 underlying shares. Each common share was converted into the right to receive $3.16 in cash per share plus one contingent value right (CVR). Each in-the-money stock option was canceled and converted into cash equal to the excess of the $3.16 per share cash consideration over its exercise price, plus one CVR for each underlying share.